Express Pharma

facebook
twitter
google_plus
Email

Browsing tag

Nandan Kulkarni

Why India’s biopharma value shift could unlock an additional $125-bn opportunity

Home
- Drug approvals
- Nutraceuticals
- Cosmeceuticals
- Pharma IT
- Policies
- Technology
- Logistics
- HR
- Biotech
- Startup Corner
- AYUSH
- More
Cover Story
Features
Specials
Guest Blogs
Interviews
Editor’s note
Events
- Upcoming Events
- Event Listings
Videos
Downloads
EP Dialogues
- Episode 1
- Episode 2

View Desktop Version